Monoclonal antibody · Acts on B-cell maturation antigen (BCMA) (TNFRSF17) · developed by Cogent Biosciences
SEA-BCMA is a humanized, afucosylated monoclonal antibody targeting B-cell maturation antigen (BCMA) on tumor cells. When combined with ACTR-expressing T-cells, it facilitates T-cell activation and cytotoxic killing of BCMA-expressing tumor cells. It is studied in multiple myeloma.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT03266692 | Phase 1 | Multiple Myeloma | Terminated | COGT |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Multiple MyelomaMultiple Myeloma in RelapseRefractory Multiple Myeloma
Updated Oct 3, 2026. Something wrong or missing? Report it on the COGT page.
See COGT's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
COGT catalysts and pipeline →